Last reviewed · How we verify
NCT04433455
Influencing Factors of Cerebrovascular Disease and Cognition in Hemodialysis Patients
trial in Hemodialysis in 20 participants. Status unknown.
31 May 2025
Quick facts
| Lead sponsor | Huashan Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 20 |
| Start date | 1 June 2020 |
| Primary completion | 31 May 2025 |
| Estimated completion | 31 May 2025 |
| Sites | 1 location across China |
Conditions studied
- Hemodialysis — all drugs for Hemodialysis →
- Cognitive Impairment — all drugs for Cognitive Impairment →
- Cerebrovascular Disorders — all drugs for Cerebrovascular Disorders →
Sponsor
Huashan Hospital
Who can join
Adults 50 to 85, any sex, with Hemodialysis or Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this observational study, the investigators evaluate the influencing factors of cerebrovascular disease and cognition in hemodialysis patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04433455
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hemodialysis
Currently open trials in the same condition.
- NCT07278973 — Hemodiafiltration Versus Hemodialysis in Older People · NA · recruiting
- NCT07438925 — Copeptin Concentration Measured in Plasma Samples and Intradialytic Blood Pressure Variation · active not recruiting
- NCT07234890 — Study to Evaluate the Effects of AV-001 on HD-induced Brain Injury. · Phase 2 · recruiting
- NCT07512895 — The Effect of Progressive Muscle Relaxation Exercises on Depression and Fatigue in Patients Receiving Hemodialysis Treat · NA · recruiting
- NCT07076888 — Aerobic Exercises and Hemodialysis Patients · NA · recruiting
Other Huashan Hospital trials
Trials by the same sponsor.
- NCT07469735 — Vorasidenib Guided by AGX PET in Recurrent/Low-grade Glioma · NA · not yet recruiting
- NCT07364487 — This is an Open-Label Study to Assess the Safety and Efficacy of GC012F in Patients With Multiple Sclerosis · EARLY_PHASE1 · withdrawn
- NCT07369830 — The Impact of Probiotic Intervention on the Gut Microbiota and Bowel Function · NA · recruiting
- NCT07185373 — Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL · Phase 2, PHASE3 · not yet recruiting
- NCT07075029 — RSV in Acute Respiratory Infection Surveillance Among Community-Dwelling Elderly Aged ≥50 Years in China · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04433455 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Huashan Hospital
- Last refreshed: 28 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04433455.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing